601607 上海医药
已收盘 12-19 15:00:00
资讯
新帖
简况
上海医药(601607.SH)：硫酸羟氯喹片获得菲律宾药品注册证书
智通财经 · 12-15
上海医药(601607.SH)：硫酸羟氯喹片获得菲律宾药品注册证书
上海医药：盐酸索他洛尔片通过仿制药一致性评价
南方财经网 · 12-15
上海医药：盐酸索他洛尔片通过仿制药一致性评价
上海医药：子公司取得药品上市许可
南方财经网 · 12-10
上海医药：子公司取得药品上市许可
上海医药股东大会通过取消监事会及半年度分红等多项议案
中金财经 · 12-10
上海医药股东大会通过取消监事会及半年度分红等多项议案
上海医药(02607)将于2026年2月6日派发中期股息每10股1.3215港元
智通财经 · 12-09
上海医药(02607)将于2026年2月6日派发中期股息每10股1.3215港元
上海医药：氨磺必利口崩片纳入国家医保目录
人民财讯 · 12-08
上海医药：氨磺必利口崩片纳入国家医保目录
上海医药：氨磺必利口崩片纳入国家医保目录 该药品境内暂无其他企业上市
每日经济新闻 · 12-08
上海医药：氨磺必利口崩片纳入国家医保目录 该药品境内暂无其他企业上市
上海医药收回1.1亿元 终止与生诺生物新型抑酸剂合作
中国经营报 · 12-07
上海医药收回1.1亿元 终止与生诺生物新型抑酸剂合作
历时4年终无果 上海医药终止与生诺生物合作协议
财中社 · 12-05
历时4年终无果 上海医药终止与生诺生物合作协议
上海医药(601607.SH)：米诺地尔搽剂获得批准生产
智通财经网 · 12-05
上海医药(601607.SH)：米诺地尔搽剂获得批准生产
每周股票复盘：上海医药（601607）拟取消监事会并修订章程
证券之星 · 11-23
每周股票复盘：上海医药（601607）拟取消监事会并修订章程
监事会竟被“一键删除”！上海医药屡犯合规问题，扣非净利下滑超两成
华夏时报网 · 11-22
监事会竟被“一键删除”！上海医药屡犯合规问题，扣非净利下滑超两成
上海医药（601607）披露拟取消监事会并修订公司章程，11月18日股价下跌0.61%
证券之星 · 11-18
上海医药（601607）披露拟取消监事会并修订公司章程，11月18日股价下跌0.61%
上海医药(02607)将派发中期股息每10股1.2元
智通财经 · 11-18
上海医药(02607)将派发中期股息每10股1.2元
每周股票复盘：上海医药（601607）两抗生素药通过一致性评价
证券之星 · 11-16
每周股票复盘：上海医药（601607）两抗生素药通过一致性评价
上海医药（601607）披露醋酸艾司利卡西平片获得美国FDA批准文号，11月11日股价上涨0.55%
证券之星 · 11-11
上海医药（601607）披露醋酸艾司利卡西平片获得美国FDA批准文号，11月11日股价上涨0.55%
上海医药(601607.SH)：注射用头孢呋辛钠及注射用氨曲南通过仿制药一致性评价
智通财经 · 11-10
上海医药(601607.SH)：注射用头孢呋辛钠及注射用氨曲南通过仿制药一致性评价
【机构调研记录】中信建投调研精智达、上海医药等5只个股（附名单）
证券之星 · 11-07
【机构调研记录】中信建投调研精智达、上海医药等5只个股（附名单）
股市必读：上海医药（601607）11月6日披露最新机构调研信息
证券之星 · 11-07
股市必读：上海医药（601607）11月6日披露最新机构调研信息
上海医药：10月31日进行路演，中信建投、新华资产等多家机构参与
证券之星 · 11-06
上海医药：10月31日进行路演，中信建投、新华资产等多家机构参与
暂无数据
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":18.03,"timestamp":1766127601000,"preClose":18.13,"halted":0,"volume":11908253,"delay":0,"changeRate":-0.0055,"floatShares":2789000000,"shares":3708000000,"eps":1.5224,"marketStatus":"已收盘","change":-0.1,"latestTime":"12-19 15:00:00","open":18.05,"high":18.1,"low":17.91,"amount":214000000,"amplitude":0.0105,"askPrice":18.04,"askSize":137,"bidPrice":18.03,"bidSize":956,"shortable":0,"etf":0,"ttmEps":1.5224,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":18.13,"symbolType":"stock","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":19.94,"lowLimit":16.32,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.88,"roa":"--","peRate":11.843142,"roe":"6.96%","epsLYR":1.23,"committee":0.317559,"marketValue":66862000000,"turnoverRate":0.0043,"status":1,"hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.83,"timestamp":1766131686008,"preClose":11.86,"halted":0,"volume":3372811,"delay":0,"premium":"-40.68"},"floatMarketCap":50289000000},"requestUrl":"/m/hq/s/601607/tweets","defaultTab":"tweets","newsList":[{"id":"2591616417","title":"上海医药(601607.SH)：硫酸羟氯喹片获得菲律宾药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616417","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616417?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:09","pubTimestamp":1765786182,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药中西制药有限公司(简称“上药中西”)生产的硫酸羟氯喹片收到菲律宾食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。硫酸羟氯喹片主要用于类风湿关节炎、青少年慢性关节炎、盘状和系统性红斑狼疮、以及由阳光引发或加剧的皮肤疾病。本次硫酸羟氯喹片(200mg)获得菲律宾食品药品监督管理局的药品注册批文，标志着公司具备了在菲律宾市场销售该药品的资格，对公司拓展海外市场带来积极影响，并积累了宝贵的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0099","BK0020","BK0175","BK0183","BK0188","BK0209","BK0012","BK0097","601607","BK1197","BK0187","BK0184","02607","BK0028"],"gpt_icon":0},{"id":"2591616286","title":"上海医药：盐酸索他洛尔片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616286","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616286?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:05","pubTimestamp":1765785951,"startTime":"0","endTime":"0","summary":"【上海医药：盐酸索他洛尔片通过仿制药一致性评价】上海医药公告，常州制药厂有限公司收到国家药监局颁发的《药品补充申请批准通知书》，盐酸索他洛尔片通过仿制药质量和疗效一致性评价。该药品主要用于转复和预防室上性心动过速、心房扑动、心房颤动、各种室性心律失常以及急性心肌梗死并发严重心律失常。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591706790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0209","BK0175","BK0020","02607","BK0099","BK0188","BK0187","BK0184","BK0196","601607","BK0097","BK0183","BK0012","BK0028","BK1197"],"gpt_icon":0},{"id":"2590301278","title":"上海医药：子公司取得药品上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2590301278","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590301278?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:53","pubTimestamp":1765353188,"startTime":"0","endTime":"0","summary":"南财智讯12月10日电，上海医药公告，公司下属上海上药信谊药厂有限公司收到国家药品监督管理局下发的《药品注册证书》，其提交的苹果酸司妥吉仑片（即SPH3127片）的药品上市许可申请已获批准。该药品为化学药品1类，适用于原发性高血压的治疗，相关项目累计已投入研发费用约2.96亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587664274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0020","BK0097","BK0187","BK0188","BK0196","BK1197","02607","BK0099","BK0184","BK0175","BK0012","601607","BK0028","BK0209"],"gpt_icon":0},{"id":"2590308537","title":"上海医药股东大会通过取消监事会及半年度分红等多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2590308537","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590308537?lang=zh_cn&edition=full","pubTime":"2025-12-10 13:17","pubTimestamp":1765343821,"startTime":"0","endTime":"0","summary":"中访网数据 上海医药集团股份有限公司于2025年12月9日召开2025年第二次临时股东大会。会议以现场结合网络投票方式审议并通过了全部四项议案。其中，关于取消监事会并修订《公司章程》及其附件的特别决议案获得高票通过，同意股份数占出席会议有效表决权股份总数的95.78%，远超三分之二门槛。此举意味着公司治理结构将从“三会一层”向“董事会中心”模式转变。备受关注的2025年半年度利润分配预案也获批准，同意票比例高达99.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31855866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0099","BK0020","BK0097","BK0188","BK0209","BK0184","601607","BK0012","BK1197","BK0175","BK0028","BK0196","BK0183","02607","BK0187"],"gpt_icon":0},{"id":"2590312678","title":"上海医药(02607)将于2026年2月6日派发中期股息每10股1.3215港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590312678","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590312678?lang=zh_cn&edition=full","pubTime":"2025-12-09 18:04","pubTimestamp":1765274665,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)公布，将于2026年2月6日派发中期股息每10股1.3215港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0099","BK0175","BK0196","BK0209","BK0020","BK0012","601607","BK0187","BK0188","BK0184","02607","BK1197","BK0183","BK0097"],"gpt_icon":0},{"id":"2589389393","title":"上海医药：氨磺必利口崩片纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589389393","media":"人民财讯","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589389393?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:02","pubTimestamp":1765180968,"startTime":"0","endTime":"0","summary":"人民财讯12月8日电，上海医药(601607)12月8日公告，公司下属公司上药中西的氨磺必利口崩片通过国家医保谈判，成功纳入《国家医保目录》。氨磺必利口崩片是赛诺菲（Sanofi）公司于1986年在法国上市的氨磺必利片的改良剂型，用于治疗成人精神分裂症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585282351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0099","BK0188","BK0020","BK0196","BK0028","BK0209","601607","BK0187","BK0012","02607","BK0175","BK1197","BK0097","BK0184"],"gpt_icon":0},{"id":"2589233893","title":"上海医药：氨磺必利口崩片纳入国家医保目录 该药品境内暂无其他企业上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2589233893","media":"每日经济新闻","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589233893?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:58","pubTimestamp":1765180734,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月8日，上海医药(601607.SH)公告称，公司下属上海上药中西制药有限公司的氨磺必利口崩片通过国家医保谈判，成功纳入《国家医保目录》，协议有效期为自2026年1月1日至2027年12月31日。截至本公告日，中国境内氨磺必利口崩片暂无其他企业上市。IQVIA数据库显示，2024年氨磺必利口服制剂的医院采购金额为1.68亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512083585276022.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585276022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0209","BK0188","BK0097","601607","BK0020","BK0028","BK0184","BK0196","BK0183","BK0012","02607","BK0187","BK0099","BK1197"],"gpt_icon":0},{"id":"2589087717","title":"上海医药收回1.1亿元 终止与生诺生物新型抑酸剂合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2589087717","media":"中国经营报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589087717?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:30","pubTimestamp":1765114201,"startTime":"0","endTime":"0","summary":"12月5日晚间，上海医药（601607.SH）发布公告，宣布其全资子公司上海上药信谊药厂有限公司（以下简称“上药信谊”）已正式终止与贵州生诺生物科技有限公司及其关联方关于新型抑酸剂X842项目的合作协议。根据双方签署的终止协议，贵州生诺方面已返还上海医药1.1亿元首付款及开发注册里程碑费用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584625889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0099","BK0028","BK0012","BK0097","BK0196","BK0209","BK1197","BK0184","601607","BK0188","BK0183","BK0187","BK0175","02607","BK0020"],"gpt_icon":0},{"id":"2589860452","title":"历时4年终无果 上海医药终止与生诺生物合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2589860452","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589860452?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:52","pubTimestamp":1764924759,"startTime":"0","endTime":"0","summary":"12月5日，上海医药（601607/02607）发布公告，宣布与贵州生诺生物科技有限公司的合作协议终止。该协议于2021年10月8日签署，涉及新型抑酸剂X842项目，允许公司全资子公司上药信谊获得该项目的独家生产和销售权。基于对外部市场的综合评估及各方经营发展规划的考虑，2025年11月18日，上药信谊与生诺生物达成了终止协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053583869660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK0183","02607","BK0187","BK0175","BK0028","BK0188","BK0099","BK0184","BK0020","BK0209","BK0012","601607","BK0097","BK0196"],"gpt_icon":0},{"id":"2589862429","title":"上海医药(601607.SH)：米诺地尔搽剂获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2589862429","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589862429?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:05","pubTimestamp":1764921958,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，公司下属上药东英(江苏)药业有限公司的米诺地尔搽剂收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。米诺地尔搽剂最早由强生公司开发，2%规格于1988年在美国上市，5%规格于1997年在美国上市。2024年1月，上药东英就该药品向国家药监局提出注册申请并获受理。截至公告日，公司针对该药品已投入的研发费用约人民币656万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0196","BK1197","BK0187","BK0012","BK0188","BK0097","BK0183","BK0209","BK0020","BK0184","BK0099","BK0175","BK0028","601607","02607"],"gpt_icon":0},{"id":"2585811103","title":"每周股票复盘：上海医药（601607）拟取消监事会并修订章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2585811103","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585811103?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:05","pubTimestamp":1763834714,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，上海医药报收于17.72元，较上周的18.32元下跌3.28%。本周关注点公司公告汇总：上海医药拟取消监事会，由董事会审计委员会行使监事会职权，并修订《公司章程》。上海医药集团股份有限公司将于2025年12月9日召开2025年第二次临时股东大会，会议采用现场投票与网络投票相结合的方式。其中，取消监事会并修订《公司章程》为特别决议议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","BK0028","BK0012","BK0097","BK0196","BK0209","BK1197","BK0184","601607","BK0188","BK0183","BK0187","BK0175","02607","BK0020"],"gpt_icon":0},{"id":"2585173352","title":"监事会竟被“一键删除”！上海医药屡犯合规问题，扣非净利下滑超两成","url":"https://stock-news.laohu8.com/highlight/detail?id=2585173352","media":"华夏时报网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585173352?lang=zh_cn&edition=full","pubTime":"2025-11-22 12:24","pubTimestamp":1763785443,"startTime":"0","endTime":"0","summary":"近年来，上海医药的整体发展节奏逐渐放缓，曾经稳健的增长态势面临新的压力。作为工商一体型药企，其核心的工业板块遭遇经营瓶颈，商业板块与工业创新之间的资源分配矛盾日益凸显，如何在短期盈利目标与长期创新战略间找到平衡，成为公司转型路上亟待破解的难题。更值得警惕的是，公司在合规管理层面的漏洞不断显现，旗下子公司因违规行为受到处罚，反映出集团对子公司的监管体系存在明显短板。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511223572004263.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511223572004263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK0187","BK0099","BK0184","BK0012","BK0188","BK0028","BK0196","BK1197","BK0183","BK0020","BK0209","BK0175","601607","BK0097"],"gpt_icon":0},{"id":"2584495343","title":"上海医药（601607）披露拟取消监事会并修订公司章程，11月18日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584495343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584495343?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:13","pubTimestamp":1763475199,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，上海医药报收于17.99元，较前一交易日下跌0.61%，最新总市值为667.13亿元。该股当日开盘18.08元，最高18.16元，最低17.94元，成交额达2.2亿元，换手率为0.44%。近日，上海医药集团股份有限公司发布公告称，公司拟取消监事会，由董事会审计委员会行使监事会职权，并修订《公司章程》及附件《股东大会议事规则》《董事会议事规则》，同时废止《监事会议事规则》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","02607","BK0020","BK0183","BK0188","601607","BK0175","BK0187","BK0028","BK0209","BK0196","BK0184","BK0099","BK1197","BK0097"],"gpt_icon":0},{"id":"2584987599","title":"上海医药(02607)将派发中期股息每10股1.2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584987599","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584987599?lang=zh_cn&edition=full","pubTime":"2025-11-18 16:49","pubTimestamp":1763455795,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，将派发截至2025年6月30日止6个月的中期股息每10股1.2元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1197","BK0183","02607","BK0187","BK0175","BK0028","BK0188","BK0099","BK0184","BK0020","BK0209","BK0012","601607","BK0097","BK0196"],"gpt_icon":0},{"id":"2583065619","title":"每周股票复盘：上海医药（601607）两抗生素药通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2583065619","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583065619?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:23","pubTimestamp":1763227389,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，上海医药报收于18.32元，较上周的17.96元上涨2.0%。本周关注点公司公告汇总：注射用头孢呋辛钠及氨曲南通过仿制药一致性评价公司公告汇总：醋酸艾司利卡西平片获美国FDA最终批准上市公司公告汇总上海医药集团股份有限公司下属上海上药新亚药业有限公司的注射用头孢呋辛钠和注射用氨曲南收到国家药监局颁发的《药品补充申请批准通知书》，通过仿制药质量和疗效一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0099","BK0020","BK0175","BK1197","BK0209","BK0188","BK0183","BK0012","02607","BK0097","BK0028","601607","BK0187","BK0184"],"gpt_icon":0},{"id":"2582541913","title":"上海医药（601607）披露醋酸艾司利卡西平片获得美国FDA批准文号，11月11日股价上涨0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582541913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582541913?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:23","pubTimestamp":1762852983,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，上海医药报收于18.37元，较前一交易日上涨0.55%，最新总市值为681.23亿元。近日，上海医药集团股份有限公司发布公告称，公司下属上海上药中西制药有限公司收到美国FDA通知，其申报的醋酸艾司利卡西平片简略新药申请已获得最终批准上市。该药品用于治疗4岁及以上患者的癫痫部分性发作，最早于2013年在美国上市。目前该药品在美国已有多个仿制药上市，2024年美国市场销售额约为3.82亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100027989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0099","BK0188","BK0020","BK0196","BK0028","BK0209","601607","BK0187","BK0012","02607","BK0175","BK1197","BK0097","BK0184"],"gpt_icon":0},{"id":"2582407608","title":"上海医药(601607.SH)：注射用头孢呋辛钠及注射用氨曲南通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2582407608","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582407608?lang=zh_cn&edition=full","pubTime":"2025-11-10 15:38","pubTimestamp":1762760292,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，公司下属上海上药新亚药业有限公司的注射用头孢呋辛钠、注射用氨曲南收到国家药品监督管理局颁发的《药品补充申请批准通知书》，前述药品通过仿制药质量和疗效一致性评价。注射用氨曲南适用于治疗敏感革兰氏阴性菌引起的感染：尿路、下呼吸道感染、败血症、皮肤和皮肤结构感染、腹腔内感染和妇科感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK1197","BK0028","BK0209","BK0183","02607","BK0020","BK0099","BK0175","BK0012","BK0184","BK0187","BK0188","601607","BK0097"],"gpt_icon":0},{"id":"2581042070","title":"【机构调研记录】中信建投调研精智达、上海医药等5只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2581042070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581042070?lang=zh_cn&edition=full","pubTime":"2025-11-07 08:04","pubTimestamp":1762473894,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月6日披露的机构调研信息，中信建投近期对5家上市公司进行了调研，相关名单如下：1）精智达 调研纪要：2025年前三季度，公司实现营业收入75,304.00万元，同比增长33.00%。4）海新能科 调研纪要：公司前三季度业绩实现扭亏为盈。前三季度毛利率下滑主因低毛利的智能售货系统收入增长。旗下最近一年表现最佳的公募基金产品为中信建投悦享6个月持有期债券C，最新单位净值为2.74，近一年增长148.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700005589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","BK0020","601607","BK0175","BK0187","BK0099","BK0276","BK0251","601066","688627","BK0196","BK0097","BK0188","BK1197","BK0012","BK0183","BK0028","BK0209","BK0184"],"gpt_icon":0},{"id":"2581742015","title":"股市必读：上海医药（601607）11月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2581742015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581742015?lang=zh_cn&edition=full","pubTime":"2025-11-07 01:45","pubTimestamp":1762451119,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，上海医药报收于17.86元，上涨0.0%，换手率0.38%，成交量10.54万手，成交额1.88亿元。来自公司公告汇总：上海医药拟取消监事会，由董事会审计委员会行使监事会职权，相关议案尚需股东大会审议。下属企业上海上药中西制药有限公司的枸橼酸托法替布缓释片获国家药监局批准生产，注册分类为化学药品4类，用于类风湿关节炎、银屑病关节炎和强直性脊柱炎，2024年中国大陆医院采购金额为5404.99万元，累计研发投入约1941.92万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700001090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0184","BK0028","BK0196","BK0209","BK0175","02607","601607","BK0187","BK0020","BK0183","BK0188","BK1197","BK0099","BK0097","BK0012"],"gpt_icon":0},{"id":"2581050832","title":"上海医药：10月31日进行路演，中信建投、新华资产等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2581050832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581050832?lang=zh_cn&edition=full","pubTime":"2025-11-06 17:33","pubTimestamp":1762421629,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年11月6日上海医药发布公告称公司于2025年10月31日进行路演，中信建投、新华资产、中邮保险、建信养老、其他34家机构、中信证券、国盛证券、中金公司、银河证券、兴业证券、天风证券、浙商证券、UBS参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600027597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","BK0183","BK0020","601607","BK0276","BK0175","BK0188","BK0012","601066","BK0196","BK0184","BK0209","BK0187","BK0099","BK1197","BK0028","BK0097"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766154323048,"stockEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.0112},{"period":"6month","weight":0.0538},{"period":"1year","weight":-0.1489},{"period":"ytd","weight":-0.1234}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"0人","perCapita":"--","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}